Troleandomycin
Systematic (IUPAC) name | |
---|---|
(3R,5R,6R,7S,8R,11R,12S,13R,14S,15S)-12-[(4-O-acetyl-2,6-dideoxy-3-O-methyl-α-L-arabino-hexopyranosyl)oxy]-14-{[2-O-acetyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy}-5,7,8,11,13,15-hexamethyl-4,10-dioxo-1,9-dioxaspiro[2.13]hexadec-6-yl acetate | |
Clinical data | |
AHFS/Drugs.com | Multum Consumer Information |
MedlinePlus | a604026 |
Identifiers | |
CAS Number | 2751-09-9 |
ATC code | J01FA08 (WHO) |
PubChem | CID 5284630 |
DrugBank | DB01361 |
ChemSpider | 4447675 |
UNII | C4DZ64560D |
KEGG | D01322 |
ChEBI | CHEBI:45735 |
ChEMBL | CHEMBL564085 |
Chemical data | |
Formula | C41H67NO15 |
Molar mass | 813.968 g/mol |
| |
| |
(what is this?) (verify) |
Troleandomycin is a macrolide antibiotic. It is sold in Italy (branded Triocetin) and Turkey (branded Tekmisin).
Troleandomycin is a CYP3A4 inhibitor that may cause drug interactions.
|
This article is issued from Wikipedia - version of the Sunday, April 03, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.